Johnson & Johnson Ordered To Pay $844 Million For Role In Opiate Crisis

Johnson & Johnson Ordered To Pay $844 Million For Role In Opiate Crisis

In a landmark ruling, Oklahoma judge Thad Balkman ruled against pharmaceutical giant Johnson & Johnson today in the first trial meant to extract retribution from drugmakers for fuelling the unprecedented wave of opiate-related overdoses and deaths in the United States.

The case, opened by Oklahoma Attorney General Mike Hunter, originally targeted Purdue Pharma and Teva Pharmaceuticals in addition to Johnson & Johnson. The former two firms reportedly settled without admitting blame for $US270 ($399) million and $US85 ($125) million, respectively.

Expected fines for Johnson & Johnson ranged anywhere from $US500 ($738) million to $US5 ($7) billion. Upon news that Judge Balkman had hewed towards the lower end of that spectrum, stocks rose for many pharma companies, Johnson & Johnson included. In his $US572 ($844) million decision today, Balkman said Johnson & Johnson had engaged in “misleading marketing and promotion of opioids” which “compromised the health and safety of thousands of Oklahomans.”

Although the decision is almost certain to be appealed, Judge Balkman’s decision makes it that much more likely other states will pursue similar tactics against pharma companies, many of which had a direct hand in aggressively pushing opiate-based painkillers to patients.

The U.S. Centres for Disease Control and Prevention estimates that over 47,000 died of opiate overdoses in the U.S. in 2017 alone. When the 18 preceding years are included, that number jumps to over 400,000.